
AETHLON MEDICAL INC
99
Recent developments include a significant share price surge following the announcement of a merger with North Immunology and associated financing, ongoing clinical trial progress, regulatory engagement reaffirmations, and capital raising activities.
- On September 17, 2026, Aethlon Medical announced a merger agreement with North Immunology, triggering a share price surge of over 470% and a $180 million financing round [N2].
- The company has reaffirmed regulatory engagement plans for the Hemopurifier, with positive market reactions noted [N8].
- Aethlon Medical completed enrollment and treatment of cohorts in its Australian oncology clinical trial, with safety reviews supporting progression [N5][N7].
- The company priced a $4 million follow-on offering in July 2026 to support operations [N6].
- Recent quarterly earnings reports indicate a narrower loss and ongoing clinical development activities [N5].
- Biotech sector coverage highlights Aethlon among stocks in focus due to recent developments and clinical progress [N3].
- Weekly biotech market summaries include Aethlon alongside other companies with approvals, deals, and operational changes [N1].
- Biotech gainers reports note Aethlon's key developments and stock performance in August 2026 [N4].
Aethlon Medical, Inc. focuses on developing the Hemopurifier, a proprietary lectin-affinity extracorporeal device designed to remove harmful extracellular vesicles and enveloped viruses from blood plasma. The device targets unmet medical needs in oncology, life-threatening viral infections, organ transplantation, and other diseases where EVs contribute to progression. The Hemopurifier has been evaluated in multiple clinical studies involving patients with viral infections and cancer, demonstrating safety and virus removal capabilities. The company is advancing clinical development primarily through a dose-finding oncology trial in Australia and maintains regulatory approvals and Expanded Access protocols for viral indications including Ebola. Preclinical research supports potential broader applications in diseases such as Long COVID and cancer metastasis. The company is regulated by the FDA's Center for Devices and Radiological Health and is exploring manufacturing scale-up and supplier qualification. Aethlon recently entered into a merger agreement with North Immunology, which may significantly alter its business focus and shareholder structure.
Aethlon Medical, Inc. is a clinical-stage medical therapeutic company developing the Hemopurifier, an investigational device designed to remove enveloped viruses and extracellular vesicles implicated in cancer and infectious diseases. The Hemopurifier has received FDA Breakthrough Device designation for oncology and viral indications and is undergoing clinical trials in Australia and the US. Financial data as of September 30, 2026, shows cash and equivalents of approximately $6.5 million, a current ratio of 5.37, and a net loss of $2.62 million for the quarter. The company announced a merger agreement with North Immunology, Inc. in September 2026, which is subject to multiple conditions and anticipated to result in significant dilution and operational changes. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
The Hemopurifier's unique mechanism of removing disease-associated extracellular vesicles and enveloped viruses addresses significant unmet medical needs in oncology and life-threatening viral infections. Positive clinical trial safety data and FDA Breakthrough Device designations support its potential therapeutic value. Preclinical studies suggest broader applicability in diseases such as Long COVID and cancer metastasis. The recent merger with North Immunology and associated financing provide resources to support development and expand the combined company's pipeline. Continued regulatory engagement and clinical progress may enhance the device's commercial prospects.
Aethlon Medical faces risks including the uncertainty of clinical trial outcomes, regulatory approvals, and the ability to commercialize the Hemopurifier. The merger with North Immunology introduces integration risks, potential dilution of existing shareholders, and a shift in business focus that may affect the legacy Hemopurifier program. Financial losses and the need for additional capital raise concerns about sustainability without successful financing or monetization of assets. Manufacturing scale-up and supplier qualification delays could impact timelines. Market acceptance and competition in the medical device and immunotherapy sectors remain challenges.
Aethlon Medical's moat is based on its proprietary lectin-affinity technology embodied in the Hemopurifier device, which uniquely targets and removes extracellular vesicles and enveloped viruses from blood plasma. The device has received FDA Breakthrough Device designation for two distinct indications, reflecting regulatory recognition of its novel mechanism and potential clinical impact. The company has established clinical trial experience, regulatory approvals including Expanded Access protocols, and a patent portfolio supporting its technology. Its specialized manufacturing process and ongoing regulatory interactions create barriers to entry. However, the clinical-stage status and need for further approvals mean the moat is contingent on successful development and commercialization.
• Merger Completion Risk: The proposed merger with North Immunology is subject to multiple conditions including stockholder approvals and regulatory clearances. Failure to complete the merger could materially adversely affect Aethlon's business, financial condition, and stock price [S2].
• Dilution and Ownership Changes: The merger will result in substantial dilution of existing stockholders and significant changes to business operations and capitalization, potentially impacting shareholder value [S2].
• Clinical and Regulatory Uncertainty: The Hemopurifier is in clinical-stage development with ongoing trials. Success depends on favorable clinical outcomes, regulatory approvals, and manufacturing scale-up, which are uncertain [S1].
• Financial Sustainability: The company has reported net losses and relies on financing activities. Additional capital may be required to continue or expand clinical development beyond current plans [S2].
• Operational Restrictions During Merger: The merger agreement imposes restrictions on business activities and strategic flexibility, which could limit Aethlon's ability to pursue alternative transactions or business opportunities [S2].
Business trends: Continued clinical development of the Hemopurifier in oncology and viral indications, supported by regulatory designations and preclinical research; merger with North Immunology introduces a strategic shift.
Execution milestones: Completion of ongoing clinical trial cohorts in Australia, regulatory approvals for manufacturing and supplier qualification, successful merger closing and integration, and capital raising activities.
Key risks: Uncertainty of merger completion and integration, clinical and regulatory approval risks for the Hemopurifier, financial sustainability amid net losses and dilution, and operational restrictions during merger pendency.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Aethlon Medical, Inc. is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage investigational immunotherapeutic device designed to remove enveloped viruses and extracellular vesicles (EVs) from biological fluids, targeting oncology, life-threatening infectious diseases, organ transplantation, and other diseases where EVs contribute to progression [S1].
- The Hemopurifier uses proprietary lectin-based technology and has been evaluated in human studies involving 173 treatment sessions in 44 patients with viral infections or cancer, showing a benign safety profile consistent with extracorporeal therapy [S1].
- The FDA has granted the Hemopurifier Breakthrough Device designation for treatment of advanced/metastatic cancer unresponsive to standard therapy and for life-threatening viruses without approved therapies [S1].
- Aethlon is conducting a safety, feasibility, and dose-finding clinical trial in Australia for patients with solid tumors resistant to anti-PD-1 monotherapy, with enrollment completed for two cohorts and progression to a third cohort after DSMB safety reviews; no serious adverse events or dose-limiting toxicities related to the device have been reported [S1].
- The company previously received regulatory approval for a similar oncology trial in India but chose not to proceed to conserve resources and focus on the Australian trial [S1].
- The Hemopurifier has been used under FDA and international regulatory frameworks to treat patients with Ebola, HIV, hepatitis C, and SARS-CoV-2, demonstrating virus removal and safety in small-scale or early feasibility studies [S1].
- The company maintains an open IDE for viral indications, including Expanded Access protocols approved by FDA and Health Canada for Ebola virus treatment, allowing treatment in multiple centers [S1].
- Preclinical studies show the Hemopurifier can remove platelet-derived extracellular vesicles implicated in various diseases including cancer, lupus, multiple sclerosis, Alzheimer's, sepsis, acute and Long COVID [S1].
- Aethlon has published preclinical research on the Hemopurifier's ability to remove EVs and microRNA cargo from perfused kidneys and plasma from Long COVID patients, supporting potential broader applications [S1].
- The Hemopurifier is classified as a combination product regulated by the FDA's Center for Devices and Radiological Health and can be used with approved dialysis machines or potentially as a proprietary closed system [S1].
- Clinical trials include a US Phase 1 trial combining Hemopurifier with pembrolizumab in head and neck cancer patients, with limited enrollment and exploratory efficacy analyses [S1].
- Financial snapshot as of 2026-09-30 shows cash and equivalents of $6.49 million, current assets of $6.86 million, current liabilities of $1.28 million, a current ratio of 5.37, and a net loss of $2.62 million for the quarter; basic and diluted EPS were -$2.60 [S2].
- The company disclosed that financial figures are summarized from the latest SEC filings and provided for informational purposes only [S2].
- On September 17, 2026, Aethlon entered into a merger agreement with North Immunology, Inc., involving a two-step merger transaction subject to multiple conditions including stockholder approvals and Nasdaq listing application [N2][S2].
- The merger is expected to result in substantial dilution of existing stockholders and significant changes to business operations, with the combined company focusing on North Immunology's pipeline [S2].
- The company has incurred and expects to continue incurring significant expenses related to the merger and has implemented workforce reductions and reduced operating expenditures while maintaining support for the Australian oncology trial [S2].
- Recent news highlights include a share price surge over 470% following the North Immunology merger announcement and $180 million financing [N2].
- Aethlon Medical has priced a $4 million follow-on offering in July 2026 and a $4.5 million public offering in September 2025 [N6].
- The company has reaffirmed regulatory engagement plans for the Hemopurifier, with stock price increases noted following such announcements [N8].
- Recent quarterly earnings transcripts and reports indicate narrowing losses and ongoing clinical development progress [N5][N7].
Generated 2026-11-13
- S1 | 2026-06-10 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-09-18 | www.nasdaq.com | Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead | https://www.nasdaq.com/articles/weekly-buzz-rare-bayry-win-approvals-sion-cuts-jobs-gsk-deals-azn-rhhby-lead
- N2 | 2026-09-17 | www.nasdaq.com | Aethlon Medical Shares Surge Over 470% On North Immunology Merger, $180M Financing | https://www.nasdaq.com/articles/aethlon-medical-shares-surge-over-470-north-immunology-merger-180m-financing
- N3 | 2026-09-17 | www.nasdaq.com | Biotech Stocks In Focus: Aethlon, Tiziana, Capricor, Firefly & Clearmind | https://www.nasdaq.com/articles/biotech-stocks-focus-aethlon-tiziana-capricor-firefly-clearmind
- N4 | 2026-08-28 | www.nasdaq.com | Biotech Gainers: QNRX Leads Gains As AEMD, DWTX And FRNM Report Key Developments | https://www.nasdaq.com/articles/biotech-gainers-qnrx-leads-gains-aemd-dwtx-and-frnm-report-key-developments
- N5 | 2026-08-28 | www.nasdaq.com | Aethlon Posts Narrower Q1 Loss, Stock Jumps | https://www.nasdaq.com/articles/aethlon-posts-narrower-q1-loss-stock-jumps
- N6 | 2026-07-06 | www.nasdaq.com | Aethlon Medical Prices $4 Million Follow-On Offering | https://www.nasdaq.com/articles/aethlon-medical-prices-4-million-follow-offering
- N7 | 2026-06-10 | www.nasdaq.com | Aethlon (AEMD) Q4 2026 Earnings Transcript | https://www.nasdaq.com/articles/aethlon-aemd-q4-2026-earnings-transcript
- N8 | 2026-05-26 | www.nasdaq.com | Aethlon Medical Reaffirms Regulatory Engagement Plans For Hemopurifier; Stock Up | https://www.nasdaq.com/articles/aethlon-medical-reaffirms-regulatory-engagement-plans-hemopurifier-stock
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


